VOLUME 10 (2019)
Table of Contents
Editorial
|
| TIL therapy and antiCTLA4: can they coexist |
|
https://doi.org/10.18632/oncotarget.26509
|
| 1-2 |
|
| Multidimensional intratumour heterogeneity in neuroblastoma |
|
https://doi.org/10.18632/oncotarget.26524
|
| 3-5 |
|
| Role of acid sphingomyelinaseinduced ceramide generation in response to radiation |
|
https://doi.org/10.18632/oncotarget.26526
|
| 6-7 |
|
| Phase 3 LILAC study sets standard for clinical evaluation of oncology biosimilars |
|
https://doi.org/10.18632/oncotarget.26528
|
| 8-9 |
|
| Combination of lenalidomide and vitamin D enhances MOR202mediated cytotoxicity of macrophages: It takes three to tango |
|
https://doi.org/10.18632/oncotarget.26531
|
| 10-12 |
Research Perspectives
|
| Simplifying checkpoint inhibitor delivery through in vivo generation of synthetic DNAencoded monoclonal antibodies DMAbs |
|
https://doi.org/10.18632/oncotarget.26535
|
| 13-16 |
Research Papers
|
| Clinical characteristics treatment outcomes and potential novel therapeutic options for patients with neuroendocrine carcinoma of the prostate |
|
https://doi.org/10.18632/oncotarget.26523
|
| 17-29 |
|
| FGFR1β is a driver isoform of FGFR1 alternative splicing in breast cancer cells |
|
https://doi.org/10.18632/oncotarget.26530
|
| 30-44 |
|
| Role of miRNA in the regulation of cannabidiolmediated apoptosis in neuroblastoma cells |
|
https://doi.org/10.18632/oncotarget.26534
|
| 45-59 |
|
| Role of long noncoding RNAs in disease progression of early stage unmutated chronic lymphocytic leukemia |
|
https://doi.org/10.18632/oncotarget.26538
|
| 60-75 |
|
| Prospective clinical trial of 12fraction carbonion radiotherapy for primary renal cell carcinoma |
|
https://doi.org/10.18632/oncotarget.26539
|
| 76-81 |
Copyright © 2026 Rapamycin Press LLC dba Impact Journals
Oncotarget ® is a registered trademark of Rapamycin Press LLC
Impact Journals ® is a registered trademark of Rapamycin Press LLC
RAPAMYCIN PRESS ® is a registered trademark of Rapamycin Press LLC